T44.4X5 Category · further specificity required Adverse effect of predominantly alpha-adrenoreceptor agonists
ICD-10-CM T44.4X5 identifies “Adverse effect of predominantly alpha-adrenoreceptor agonists” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 19: Injury, poisoning and certain other consequences of external causes
Code-level instructions
No additional notes.
Inherited instructions
Chapters 19 · Injury, poisoning and certain other consequences of external causes (S00-T88)
Excludes 22
- birth trauma (P10-P15)
- obstetric trauma (O70-O71)
Use additional code1
code to identify any retained foreign body, if applicable (Z18.-)
Note2
- Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
- The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.
T36-T50 · Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances (T36-T50)
Includes4
- adverse effect of correct substance properly administered
- poisoning by overdose of substance
- poisoning by wrong substance given or taken in error
- underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed
Excludes 11
toxic reaction to local anesthesia in pregnancy (O29.3-)
Excludes 25
Code first7
Use additional code4
Note1
The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
T44 · Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system
Seventh character1
The appropriate 7th character is to be added to each code from category T44
A — initial encounter
D — subsequent encounter
S — sequela
T44.4 · Poisoning by, adverse effect of and underdosing of predominantly alpha-adrenoreceptor agonists
Inclusion terms1
Poisoning by, adverse effect of and underdosing of metaraminol
More specific codes
T44.4X5AAdverse effect of predominantly alpha-adrenoreceptor agonists, initial encounterBillable / specificT44.4X5DAdverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounterBillable / specificT44.4X5SAdverse effect of predominantly alpha-adrenoreceptor agonists, sequelaBillable / specificOfficial index references
Official index references (17)
Agonist (1)
- Agonist › predominantly › alpha-adrenoreceptorDrugs and chemicals
Aplonidine (1)
- AplonidineDrugs and chemicals
Apraclonidine(hydrochloride) (1)
- Apraclonidine(hydrochloride)Drugs and chemicals
Cyclopentamine (1)
- CyclopentamineDrugs and chemicals
Etilefrine (1)
- EtilefrineDrugs and chemicals
Gepefrine (1)
- GepefrineDrugs and chemicals
Levarterenol (1)
- LevarterenolDrugs and chemicals
Metaraminol (1)
- MetaraminolDrugs and chemicals
Methoxamine (1)
- MethoxamineDrugs and chemicals
Noradrenaline (1)
- NoradrenalineDrugs and chemicals
Norepinephrine (1)
- NorepinephrineDrugs and chemicals
Norfenefrine (1)
- NorfenefrineDrugs and chemicals
Oxedrine (1)
- OxedrineDrugs and chemicals
Paredrine (1)
- ParedrineDrugs and chemicals
Phenylephrine (1)
- PhenylephrineDrugs and chemicals
Privine (1)
- PrivineDrugs and chemicals
Propyl (1)
- Propyl › hexadrineDrugs and chemicals
History
Code history
Latest recorded change · FY2025 · 04-01
Effective from
- Inherited rules changed
Adverse effect of predominantly alpha-adrenoreceptor agonists
Category — select a more specific code
CDC/NCHS · FY2025 · 04-01All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | Inherited rules changed |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | Inherited rules changed |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | Inherited rules changed |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.